EP2688474A2 - Bodily fluid analysis device - Google Patents
Bodily fluid analysis deviceInfo
- Publication number
- EP2688474A2 EP2688474A2 EP12711155.7A EP12711155A EP2688474A2 EP 2688474 A2 EP2688474 A2 EP 2688474A2 EP 12711155 A EP12711155 A EP 12711155A EP 2688474 A2 EP2688474 A2 EP 2688474A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- bodily fluid
- electrodes
- pair
- display
- controller
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 87
- 238000004458 analytical method Methods 0.000 title claims abstract description 47
- 239000000758 substrate Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 14
- 239000003292 glue Substances 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000004888 barrier function Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 description 92
- 230000002745 absorbent Effects 0.000 description 83
- 239000002250 absorbent Substances 0.000 description 83
- 238000005259 measurement Methods 0.000 description 80
- 239000008280 blood Substances 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 43
- 230000004913 activation Effects 0.000 description 32
- 238000012360 testing method Methods 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 230000008569 process Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 11
- 239000013076 target substance Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000003990 capacitor Substances 0.000 description 5
- 239000012491 analyte Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1477—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means non-invasive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient; User input means
- A61B5/742—Details of notification to user or communication with user or patient; User input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0204—Operational features of power management
- A61B2560/0209—Operational features of power management adapted for power saving
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0204—Operational features of power management
- A61B2560/0214—Operational features of power management of power generation or supply
- A61B2560/0219—Operational features of power management of power generation or supply of externally powered implanted units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0295—Strip shaped analyte sensors for apparatus classified in A61B5/145 or A61B5/157
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/04—Arrangements of multiple sensors of the same type
- A61B2562/046—Arrangements of multiple sensors of the same type in a matrix array
Definitions
- This invention relates to a bodily fluid analysis device.
- diabetes sufferers may be provided with quantities of insulin, for instance by injection, sometimes a number of times daily.
- the quantity of insulin that is appropriate depends on the person's blood glucose level, so blood glucose level measurement can also occur a number of times daily.
- Blood glucose level measurement typically is a multi stage process requiring a number of separate pieces of equipment.
- a user may be required to carry around a bulky electronic blood glucose meter as well as a supply of test strips and lancet. After lancing the skin to elicit a blood sample, a user must transfer the blood to the test strip, activate the meter and present or insert the test strip into the meter in order to obtain a measurement.
- US 7,378,007 B2 discloses a device having a lancet and electrochemical sensor for measuring a blood glucose level.
- this document discloses (see column 8) that the sensor and display of the device are disposed on or within a main housing of the device. Separate from the main housing of the device is a sensor disk supporting a plurality of radially arranged sensors. The sensor disk is secured to a spacer ring which is in connection with the main housing via a cam ring. The cam ring may be secured to the main housing by a screw or similar fastening.
- US 7,378,007 B2 discloses a complex, multi-part device in which various components of the device are supported on separate substrates which are then assembled together.
- US 7,641 ,857 discloses a measuring apparatus having a test element containing an analyte. Adjacent to the test element is a detector for detecting for detecting, optically or electrochemical ly, a change in the test field and generating an electrical signal. This electrical signal is used to form a measurement result. This document discloses no other detectors or electrical signals.
- a first aspect of the invention provides an apparatus comprising a substrate, the substrate having supported thereon:
- plural collectors each for collecting a bodily fluid from the surface of a body part placed adjacent thereto;
- an analyser for analysing each collected bodily fluid wherein the analyser comprises a controller, wherein each of the at least two pairs of electrodes are connected to the analyser and wherein the analyser is configured to analyse at least one electrical signal received via a first pair of the at least two pairs of electrodes; and a display for displaying an indication of a result of each analysis, wherein the apparatus is configured to activate the analyser in response to a predetermined electrical signal received via a second pair of the at least two pairs of electrodes.
- a bodily fluid collecting end of each of the collectors may be covered by a removable seal.
- Each removable seal may provide a fluid impermeable barrier around the bodily fluid collecting end of the respective collector.
- the apparatus may be configured to activate the display in response to a predetermined electrical signal received via the second pair of electrodes.
- the apparatus may be configured to activate the display in response to a predetermined electrical signal received via a third pair of the at least one pair of electrodes integral with each collector.
- Each second pair of electrodes may be located further from a bodily fluid collecting end of the respective collector than each first pair of electrodes.
- Each third pair of electrodes may be located closer to a bodily fluid collecting end of each collector than each first pair of electrodes.
- the apparatus may further comprise an adjustable calibration resistor.
- the substrate may be disc shaped and the plural collectors may be arranged generally radially on the substrate.
- the apparatus may further comprise a cover plate and a glue layer disposed between the substrate and the cover plate, wherein the glue layer is structured so as to define a maximum extent of each of the collectors.
- the cover plate may have a plurality of notches in an outer edge of the cover plate, each notch being aligned with a respective collector.
- a second aspect of the invention provides a method for analysing a bodily fluid sample, comprising:
- a bodily fluid analysis device receiving a bodily fluid sample at one of a plurality of bodily fluid collectors formed therewith;
- the bodily fluid analysis device detecting a predetermined electrical signal received via a second pair of at least two pairs of electrodes integral with each bodily fluid collector;
- the bodily fluid analysis device in response to detecting the predetermined signal, activating a controller and analysing the collected bodily fluid sample using the controller by analysing at least one electrical signal received via a first pair of the at least two pairs of electrodes; and the bodily fluid analysis device displaying an indication of a result of the analysis.
- Figure 1 is a side-on view of a first embodiment of a bodily fluid analysis device according to the invention
- Figure 2 is a plan view of the bodily fluid analysis device of Figure 1 ;
- Figure 3 is a schematic illustration of some of the components of the bodily fluid analysis device of Figures 1 and 2;
- Figure 4 shows a view of the underside of a cover plate forming part of the bodily fluid analysis device of Figures 1 , 2 and 3;
- Figure 5 shows detail of a cross-section of a portion of the bodily fluid analysis device of Figures 1 to 3;
- Figure 6 is a view of the upper side of a substrate forming part of the bodily fluid analysis device of Figures 1 to 3 and shows detail of some of the components formed thereon;
- FIGS. 7A and 7B show schematic illustrations of embodiments of the invention containing activation electrodes
- Figures 8A-D show the bodily fluid analysis device of Figures 1 to 3 in an exemplary operation
- Figure 9 is a flow chart illustrating an exemplary operation of the bodily fluid analysis device of Figures 1 to 3.
- the analysis device 100 has a layered structure.
- the bottom layer comprises a substrate 102 in the form of a generally circular or disc-shaped sheet material.
- Formed on top of the substrate 102 are a number of electronic components that are described in detail below with reference to Figure 3.
- the top layer of the device 100 comprises at least one cover plate 104 which covers and protects the components formed on top of the substrate 102.
- Between the substrate 102 and the cover plate 104 is a glue layer 106.
- Each collection and testing segment 108 has a region of absorbent material 1 10 extending inwardly from the edge of the bodily fluid analysis device 100.
- the regions of absorbent material 1 10 are substantially rectangular in shape, although other shapes are possible.
- Each region of absorbent material 1 10 is formed directly onto the substrate 102.
- the extent of the absorbent material 1 10 is illustrated by the dashed lines in Figure 2.
- Each segment 108 also has at least one pair of electrodes, as described in greater detail below with reference to Figure 3.
- Notches 1 12 in the form of V-shaped indentations are provided in the outer edge of cover plate 104 at the position of each segment 108. Vent holes 1 14 are provided in the cover plate 104 at positions coincident with an innermost extent of each region of absorbent material 1 10.
- the substrate 102 also supports a display 1 16.
- the display 1 16 is located at or near the centre of the bodily fluid analysis device 100.
- the bodily fluid analysis device 100 also has removable seals 1 18 covering each notch 1 12 and the exposed ends of the regions of absorbent material 1 10. The removable seals 1 18 are attached to the underside of the substrate 102, to the upper face of cover plate 104 and to the outer edge of the bodily fluid analysis device 100.
- the substrate 102 is formed of a non absorbent material.
- the substrate 102 may be a plastic material or any other suitable material such as silicon.
- the substrate is preferably rigid.
- the cover plate 104 may be formed of any suitable material, for example a rigid or flexible plastic material.
- Each of the segments 108 is arranged radially on the bodily fluid analysis device 100.
- the entire outer edge/circumference of the bodily fluid analysis device 100 may support collection and testing segments 108.
- the segments 108 may be arranged into two or more groups supported on different parts of the outer edge/circumference of the bodily fluid analysis device 100.
- the bodily fluid analysis device 100 may support between 15 and 50, preferably between 25 and 35 collection and testing segments 108.
- Each of the segments 108 contains a region of absorbent material 1 10 which is also arranged radially on the bodily fluid analysis device 100 such that a first end of the absorbent material 1 10 is coincident with an outer edge or circumference of the bodily fluid analysis device 100.
- This first end of the absorbent material 1 10 is the bodily fluid collecting end and is exposed at the circumference of the bodily fluid analysis device 100 as shown in Figure 1 .
- the absorbent material 1 10 may be formed directly onto the substrate 102 or may be glued or otherwise secured to the substrate 102.
- the absorbent material 1 10 may be disposed within the glue layer 106, such that it is abutted on either side by the glue layer 106.
- the notches 1 12 are formed in the cover plate 104 directly above the location where each region of absorbent material 1 10 meets the outer edge or circumference of the bodily fluid analysis device 100.
- the notches 1 12 extend through the whole thickness of the cover plate 104 such that a portion of the top surface of the absorbent material 1 10 is exposed.
- the absorbent material 1 10 may be a wicking material having a capillary structure.
- the absorbent material 1 10 may be a sheet material. Fluid applied to the exposed part of the absorbent material 1 10 is drawn into the body of the absorbent material 1 10 by capillary action.
- the vent holes 1 14 extend through the whole thickness of the cover plate 104 such that they contact each region of absorbent material 1 10 at an end of the absorbent material 1 10 opposed to the outer, exposed edge. The vent holes 1 14 facilitate the capillary action by allowing air within the absorbent material 1 10 to be displaced by fluid.
- the absorbent material 1 10 may contain a chemical substance such as an enzyme.
- the absorbent material 1 10 may be doped with the chemical substance during manufacture. When bodily fluid is absorbed into the material 1 10, it reacts with the chemical substance to create an electrical signal.
- the chemical substance present in the absorbent material 1 10 may be selected to react with specific target substance in the bodily fluid or to catalyze a reaction involving a target substance in the bodily fluid.
- the bodily fluid may be blood and the target substance may be blood glucose.
- the blood glucose may react with a mediator in the absorbent material 1 10.
- the mediator may oxidize the glucose and may subsequently be reoxidised at the anode to produce electrical charge, and - with a corresponding redox- reaction at the cathode - a current.
- the mediator may be any suitable substance, for example Ferricyanide/Ferrocyanide.
- An enzyme for example glucose oxidase, may be involved in the oxidation and reduction of the glucose.
- the target substance may be another component of blood, for example glycated haemoglobin (HbA1 c) or a ketone.
- the chemical substance may be present throughout the absorbent material 1 10 or it may only be present in a portion of the absorbent material 1 10.
- the absorbent material 1 10 is configured to absorb a predetermined amount of fluid. Depending on the bodily fluid which is being absorbed, the property of the fluid which is to be measured and the method by which the measurement is to be taken, the volume of fluid present in the absorbent material 1 10 may affect the measurement.
- Configuration of the absorbent material 1 10 to absorb a predetermined amount of fluid helps to improve measurement accuracy.
- the display 1 16 may be a Liquid Crystal Display (LCD), comprising an LCD fill (not shown) and a LCD cover plate (not shown).
- LCD Liquid Crystal Display
- the display 1 16 may alternatively be another type of suitable electronic display.
- the display 1 16 is configured to display a result of a measurement of a target substance in the bodily fluid.
- the removable seals 1 18 may be made of a metal foil and may be impermeable to gas and/or liquid. A removable seal may be secured to the bodily fluid analysis device 100 so as to cover the notch 1 12, exposed parts of the region of absorbent material 1 10 and the vent hole 1 14 such that no fluid is able to enter or leave the absorbent material 1 10 before the seal 1 18 is removed. Thus, the humidity (or absence of humidity) within the absorbent material 1 10 at manufacture is maintained until the time of use of the respective collection and testing segment 108.
- the removable seals 1 18 may be secured to the surface of the bodily fluid analysis device 100 by an adhesive.
- the removable seals 1 18 may each have an unsecured portion or lip which can be grasped by a user of the bodily fluid analysis device 100 and pulled in order to remove the seal 1 18.
- Each collection and testing segment 108 has its own removable seal 1 18 such that the removal of one seal 1 18 does not cause any exposure of the absorbent material 1 10 of another segment 108.
- FIG. 3 a schematic view is shown in which electronic components supported on the substrate 102 are illustrated.
- the upper surface of the substrate 102 is shown.
- the substrate supports a controller 120, display electronics 1 16 and batteries 122.
- Each collection and testing segment 108 has a pair of
- the controller 108 is connected to each pair of measurement electrodes 124 via conductive paths 126. Each pair of measurement electrodes 124 overlaps with a respective region of absorbent material 1 10, the extent of which is illustrated by the dashed line.
- the display 1 16, controller 120 and batteries 122 are all located at or near the centre of the bodily fluid analysis device 100.
- a calibration resistor 128 is disposed on a conductive path linking the controller 120 to one of the measurement electrodes 124.
- the controller 120 is also connected to the display 1 16 via one or more conductive paths.
- the batteries 122 are disposed on a conductive path which begins and ends at the controller 120.
- the controller 120 is configured to receive electrical signals from the measurement electrodes 124 and to send control signals to the display 1 16.
- the measurement electrodes 124 may be made of any conductive material, for example carbon or a metal.
- the controller 120 may be a microcontroller or integrated circuit of any suitable type.
- the controller 120 may store software or algorithms in flash memory (not shown) and may have volatile memory such as RAM (not shown) for executing the software.
- the controller 120 is connected to each pair of measurement electrodes 124 in order to measure a property of the bodily fluid sample absorbed in the respective region of absorbent material 1 10.
- the batteries 122 are configured to provide power to the controller 120 and the display 1 16.
- the batteries 122 have an energy storage capacity which is sufficient only to power the controller 120 and to power the display 1 16 for a reasonable time, e.g. up to one hour.
- the batteries 122 may be replaced with another source of power such as a capacitor able to collect energy from radio frequency signals emitted by a mobile transmitting device such as a mobile phone.
- a user of the device 100 may be able to power or charge the device 100 using an application on their mobile phone or the device 100 may charge by being in close proximity to the user's mobile phone for a short time.
- the device 100 may also be able to collect energy from ambient electromagnetic radiation.
- the batteries 122 are replaced with means for collecting energy from a user of the device 100.
- the device 100 may have an area which the user compresses between their fingers to impart energy to the device 100.
- the device 100 may contain both batteries 122 and other means for collecting energy.
- the measurement electrodes 124 are disposed directly onto the substrate 102 and overlap with at least a portion of the absorbent material 1 10.
- the absorbent material 1 10 may be applied to the substrate 102 after the measurement electrodes 124.
- the measurement electrodes 124 may comprise a pair of electrodes spaced apart. The space between the electrodes 124 is at least partially occupied by absorbent material 1 10.
- the measurement electrodes 124 are configured to transmit electrical signals generated by the reaction of bodily fluid with a chemical substance present in the absorbent material 1 10 to the controller 120 so that a property of the bodily fluid can be measured. This property may be a concentration of a specific substance present in the bodily fluid.
- Each resistor 128 is disposed on a conductive path linking the controller 120 to one of the measurement electrodes 124. This allows the electrical resistance of the circuit path formed by the controller 120, measurement electrodes 124 and absorbent material 1 10 to be predetermined. The controller 120 may rely on having an accurate value for the resistance of this circuit path in order to produce an accurate measurement.
- the resistors 128 may be printed circuit resistors and may be printed on the substrate 102 with a carbon containing ink, for example.
- the resistors 128 may be used for calibration, for example to adjust a lot to lot manufacturing accuracy of the device 100. For example, after determining a calibration value of a lot of bodily fluid analysis devices 100 during production, the resistance of the resistor 128 may be adjusted by laser cutting or by modifying the printing process of resistor 128. The resistance of resistor 128 may be used during use of device 100 as a calibration value to adjust a measurement result.
- a single resistor 128 is disposed on a conductive path that begins and ends at the controller 120 and does not incorporate any of the pairs of measurement electrodes 124.
- the volume of bodily fluid absorbed by the absorbent material 1 10 may, in some measurement techniques and for some target substances, affect the measurement of that target substance.
- the absorbent material 1 10 may therefore be manufactured to absorb a predetermined amount of fluid. This amount may depend on the structure and number of capillaries which form the absorbent material 1 10.
- the concentration of chemical substance embedded in the absorbent material 1 10 and which reacts with the target substance in the bodily fluid may also affect the
- one device 100 of each batch may be tested after it has been manufactured in order to determine a calibration value for the devices produced in that batch.
- the electrical resistance of the measurement circuit path may need to be accurate within a small tolerance. This may be achieved by measuring a control solution with an accurate concentration of analyte, such as glucose.
- the resistors 128 can be trimmed with a laser such that their resistance is decreased. After the laser trimming a detached part of the resistor 128 no longer forms a part of the measurement circuit path. In this manner, batch variation in the properties of the absorbent material 1 10 can be corrected.
- a capacitor is used for storing a calibration value on the device 100 instead of a resistor 128. Modifying the capacitor may be done by laser cutting or the printing process during production.
- a calibration value may be stored in a non-volatile memory of the device during production, for example in the flash memory.
- no dedicated resistor 128 or capacitor may be needed for calibration.
- the display 1 16 may be a numerical display configured to display three digits. In some other embodiments the display 1 16 may be configured to display more than three digits. The best choice of display depends on the range and accuracy of the measured property required. In some embodiments, the display 1 16 may be configured to display a decimal point before or after the first or second digit. Alternatively the decimal point may be in a fixed location, for example after the second digit. Each digit of the display 1 16 may comprise a seven-segment display capable of displaying the numbers 0 to 9. Only a single connection between the controller 120 and the display 1 16 is shown, however there may be several individual connections. There may be a connection between the controller 120 and the display 1 16 for each digit, or for each segment of each digit, or there may be a multiplexed connection.
- the device 100 is preferably relatively small in size, for example about 80-120mm in diameter and less than 15mm thick. This makes the device 100 easily portable for a user such that it may be easily carried around by the user. Because the functions of a test strip and analysis device are combined in a single device of small size, a user does not need to carry a separate meter, which may be a relatively bulky item.
- Cover plate 104 has a display window 130, a controller and battery cavity 132 and absorbent material cavities 134. Notches 1 12 are provided in the outer edge of the cover plate 104 and are aligned with each absorbent material cavity 134.
- the vent holes 1 14 are provided in the cover plate 104 at the innermost end of each absorbent material cavity 134.
- the display window 130, notches 1 12 and vent holes 1 14 are cut out portions which are also visible from the upper side of the cover plate 104.
- the controller and battery cavity 132 and absorbent material cavities 134 are recesses in the underside of the cover plate 104 which do not extend through the whole thickness of the cover plate 104 and are not visible from the upper side.
- the controller and battery cavity 132 provides a space for the controller 120, batteries 122 and any other electronic components, such as resistors and capacitors, which may form a part of the power and control circuitry.
- the absorbent material cavities 134 provide a space for the region of absorbent material 1 10.
- the absorbent material cavities 134 may be large enough to allow the region of absorbent material 1 10 to expand when saturated with fluid.
- the display window 130 may have a transparent cover, such as a transparent piece of film, in order to protect the display 1 16 underneath from damage.
- the display 1 16 may comprise a transparent cover plate (not shown), which may be made of a glass material.
- Figure 5 shows a detailed cross-sectional view of the bodily fluid analysis device 100 at a position of one of the collection and testing segments 108.
- the notch 1 12 in the cover plate 104 exposes some of a top surface of the absorbent material 1 10. This makes the process of absorption of bodily fluid by the absorbent material 1 10 more efficient.
- Measurement electrodes 124 are formed directly onto the substrate 102.
- the absorbent material 1 10 may also be formed directly onto the substrate 102 and may overlie the measurement electrodes 124 as shown in Figure 5.
- Figure 6 shows a detailed view of the top surface of the substrate 102 and some of the components supported by the substrate 102.
- the glue layer 106 is omitted from Figure 5 for reasons of clarity but is shown in Figure 6.
- the glue layer 106 fills the area on the substrate between each collection and testing segment 108.
- the glue layer covers the conductive paths located between each segment 108.
- the glue layer 106 secures the cover plate 104 to the substrate 102, but also separates the segments 108 from one another. This ensures that there are no environmental impacts e.g. increased humidity, on a segment 108 when an adjacent segment is exposed and also helps to ensure that no fluid absorbed in one segment 108 can leak into another.
- the region of absorbent material 1 10 may be omitted.
- the absorbent material 100 may be replaced by a cavity with appropriate dimensions that acts as a capillary.
- the glue layer 106 may also perform the function of a spacing layer to ensure that the capillary cavity is of a suitable width.
- FIGS 3, 5 and 6 show schematic illustrations of embodiments of the invention containing activation electrodes.
- the device 100 has a pair of measurement electrodes 124 and a pair of activation electrodes 136. Both the measurement electrodes 124 and the activation electrodes 136 are connected to the controller 120 via conductive paths 126 and overlap the absorbent material 1 10. In some embodiments the electrodes may only overlap partially with the absorbent material 1 10.
- the activation electrodes 136 are configured to pass electrical signals generated in the absorbent material 1 10 to the controller 120. These signals are used as a trigger for activation of the controller 120 and the display 1 16. For example, the controller 120 may be configured to detect only signals above a certain threshold which are received from the activation electrodes 136.
- the controller 120 and display 1 16 are activated.
- the measurement electrodes 124 are located closer to the outer edge of the collection and testing segment 108 than the activation electrodes 136. Therefore, as fluid is absorbed into the absorbent material 1 10, the region between the measurement electrodes 124 is first saturated and then, provided enough fluid is available, the region between the activation electrodes 136 is saturated. This arrangement ensures that there is a sufficient quantity of bodily fluid in the region between the measurement electrodes 124 when the controller 120 and display 1 16 are activated.
- Figure 7B shows another embodiment in which there are two pairs of activation electrodes and one pair of measurement electrodes 124.
- a single collection and testing segment 108 is shown on the substrate 102 for clarity.
- the two pairs of activation electrodes are controller activation electrodes 138 and display activation electrodes 140.
- the controller activation electrodes 138 are located closest to the outer edge of the collection and testing segment 108.
- the measurement electrodes 124 are located behind the controller activation electrodes 138; further from the outer edge of the segment 108.
- the display activation electrodes 140 are located behind the measurement electrodes 124; furthest from the outer edge of the segment 108.
- the controller 120 is configured to detect only signals above a certain threshold which are received from the controller activation electrodes 138 and display activation electrodes 140. When a signal above a threshold value is detected via the controller activation electrodes 138, the controller 120 is activated. The controller 120 may then begin recording signals received via the measurement electrodes 124. When a signal above a threshold value is detected via the display activation electrodes 140, the display 1 16 is activated. The display 1 16 may be activated in a standby mode. Since the display activation electrodes 140 are located further from the outer edge of the segment 108 than the controller activation electrodes 138, the controller 120 is activated before the display 1 16. This results in the display 1 16 being activated for the shortest possible time before a reading is displayed. This reduces the total amount of power required to make a measurement of a property of a bodily fluid and to display the result of the measurement to a user of the device 100 for a given period of time. The signals from display activation electrodes 140 may also be used in the
- a measurement of an analyte in the bodily fluid For example, by measuring the time when the bodily fluid reaches the display activation electrodes 140, a measurement of the viscosity or the amount of bodily fluid can be made.
- each of the pairs of electrodes are connected to the controller 108 via separate conductive paths 126 formed on the substrate 102.
- the display 1 16, batteries 122 and resistor 128 of the device 100 may be substantially the same as when only the measurement electrodes 124 are present.
- the controller 120 and display 1 16 only draw power from the batteries 122 when active. When inactive, the current discharge from the batteries 122 is zero or close to zero such that the shelf life of the device 100 is not affected.
- each of the pairs of measurement electrodes 124 and activation electrodes are arranged in parallel with a radial line connecting the segment 108 with a centre point of the device 100, as shown in Figures 3, 5 and 6.
- each pair of electrodes is arranged
- Electrodes 7A and 7B perpendicularly to this radial line.
- the electrodes may be contained completely within the region of absorbent material 1 10. Alternatively, the electrodes may overlap partially with the absorbent material 1 10.
- the bodily fluid which is collected by the device 100 is blood and the property of the blood which is measured is the blood glucose level.
- the process of making a blood glucose level measurement with the device 100 will now be described with reference to Figures 8A-D and the flow chart of Figure 9.
- a user of the device 100 first removes one of the removable seals 1 18 from its respective collection and testing segment 108, as shown in Figure 8A. To achieve this, a user grasps and pulls an end of the removable seal 1 18 which is not secured to the device 100. Removal of the removable seal 1 18 exposes a notch 1 12, a portion of the absorbent material 1 10 and a vent hole 1 14.
- the removable seals 1 18 may be printed with numbers to allow the user to more easily monitor their usage of the device 100. In Figure 8A the user is removing the first of 30 removable seals 1 18.
- the user After removing the removable seal 1 18, the user obtains a blood sample. This can be achieved by the user in any known way, for example by using a lancet or similar to elicit blood from their finger.
- a lancet or similar to elicit blood from their finger.
- Figure 8B the user has elicited a blood sample and is about to present the blood to the exposed end of the region of absorbent material 1 10.
- Printed on the upper surface of the cover plate 104 is a unit in which the subsequent measurement is expressed. This may for example be mg/dl, mmol/l or mol/l. In some other embodiments this unit may instead be printed on a cover plate (not shown) of the display 1 16 itself. In some other embodiments, the unit of the measurement may be displayed by the display 1 16 and may only appear when the result of the measurement is shown.
- Figure 8C the user has presented the blood to the absorbent material 1 10 by pressing their finger against the edge of the device 100 at the location of the
- the alignment of the notch 1 12 with the absorbent material makes it easier for the user to ensure that they are providing their blood sample onto the absorbent material 1 10.
- the notch 1 12 may also be sized and shaped such that it exerts a pressure on a user's finger at positions either side of the lancing location. This arrangement may aid in expelling blood from the user's finger.
- the blood is absorbed into the absorbent material 1 10 by capillary action.
- the absorbent material 1 10 becomes saturated with the blood as indicated by the cross hatching.
- the blood reacts with an enzyme present in the absorbent material 1 10 or undergoes a reaction which is catalyzed by an enzyme present in the absorbent material 1 10. This reaction produces an electrical charge which may pass as a current through the measurement electrodes 124 and via the conductive paths 126 to the controller 120.
- the amount of analyte contained in the bodily fluid determines the magnitude of the electrical signal that reaches the controller 120.
- the controller 120 begins measuring signals received from the measurement electrodes 124. To achieve this, the controller 120 executes software and/or algorithms with which it has been programmed. The controller 120 is programmed to interpret signals received via the measurement electrodes 124 so as to make a measurement of a property of the bodily fluid. The controller 120 may produce a measurement based on a single signal sample received via the measurement electrodes 124. Alternatively the controller 120 may record a series of signals received via the measurement electrodes 124. The controller 120 may compute a measurement based on an analysis of the series of received signals. The property of the electrical signal measured at the controller 120 may be a current and/or voltage of the signal and may involve a time element, for instance by integrating an electrical parameter over time.
- the display 1 16 may show a standby state, for example by illuminating the bottom segment of each digit of the display 1 16, as shown in Figure 8C.
- the controller 120 has finished making its measurement of the blood glucose level of the absorbed blood sample.
- the controller 120 controls the display 1 16 to display the result of the measurement to the user.
- the display 1 16 continues to display the result of the measurement for a predetermined amount of time, for example 60 seconds.
- Figure 9 is a flow chart illustrating the process of measuring a blood glucose level using the device 100.
- the process begins at step 900.
- the user removes a removable seal 1 18 from the device 100.
- This step of the process is shown in Figure 8A.
- the user presents blood to the device 100 by pressing their finger against the notch 1 12.
- This step of the process is shown in Figure 8C.
- the blood is absorbed into the device 100 by capillary action.
- the capillary action causes the blood to fill all of the absorbent material 1 10 such that it becomes saturated.
- the blood reacts with a chemical substance embedded in the absorbent material 1 10.
- the glucose in the blood reacts with an enzyme, for example glucose oxidase or glucose dehydrogenase.
- the reaction produces electrical charge which flows as a current through the saturated absorbent material 1 10 to the measurement electrodes 126.
- the controller 120 begins measuring the blood glucose level in the absorbed blood sample.
- the controller 120 is configured to receive electrical signals produced by the reaction of the blood glucose with the enzyme in the absorbent material 1 10 via the measurement electrodes 124.
- the controller 120 may receive multiple signals in order to make the measurement.
- the signals may for example be multiple consecutive values of a voltage or a current separated over time.
- the measurement may involve a time element, for instance integrating the values over time.
- the display 1 16 is activated.
- the display 1 16 may be in a standby mode.
- This standby mode may consist of illuminating at least some of the pixels of the display. This has the added advantage of signalling to a user of the device 100 that the blood sample they have provided is of a sufficient volume and quality and that a measurement is underway. This step of the process is shown in Figure 8C.
- Steps 910 and 912 may occur substantially simultaneously.
- steps 910 and 912 may only begin once it is determined that an electrical signal received at the controller 120 via the activation electrodes is above a threshold level. This determination may be performed in hardware at the controller 120 such that the controller 120 may remain inactive during the determination.
- the device 100 may be configured such that when the absorbent material 1 10 is saturated with a blood sample of a sufficient quality, the threshold signal value is exceeded. If, after a time, no measurement result is displayed or the display 1 16 remains in a standby mode, this may indicate to a user that not enough blood has been absorbed or that the reaction rate is too low.
- step 914 it is determined if the measurement of the blood glucose level is complete.
- the controller 120 may perform the measurement relatively quickly based on a single or a few signals from the measurement electrodes 124. In some other embodiments the controller 120 may record signals over a short period of time in order to produce a more accurate measurement of the blood glucose level. If the measurement is not complete, the display continues to operate in standby mode at step 912. Once it is determined that the measurement is complete the process continues at step 916.
- the display 1 16 is caused by the controller 120 to display a result of the measurement.
- the display 1 16 may continue to display the result of the measurement for a predetermined period of time before deactivating the display 1 16. This step of the process is shown in Figure 8D.
- the process ends at step 918. After the user has used all of the collection and testing segments 108 on the device 100, the device 100 may be discarded.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Artificial Intelligence (AREA)
- Hematology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12711155.7A EP2688474B1 (en) | 2011-03-25 | 2012-03-23 | Bodily fluid analysis device and method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11159864 | 2011-03-25 | ||
| EP12711155.7A EP2688474B1 (en) | 2011-03-25 | 2012-03-23 | Bodily fluid analysis device and method |
| PCT/EP2012/055256 WO2012130773A2 (en) | 2011-03-25 | 2012-03-23 | Bodily fluid analysis device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2688474A2 true EP2688474A2 (en) | 2014-01-29 |
| EP2688474B1 EP2688474B1 (en) | 2015-02-11 |
Family
ID=44453902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP12711155.7A Not-in-force EP2688474B1 (en) | 2011-03-25 | 2012-03-23 | Bodily fluid analysis device and method |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8974747B2 (en) |
| EP (1) | EP2688474B1 (en) |
| JP (1) | JP2014508950A (en) |
| CA (1) | CA2829499A1 (en) |
| DK (1) | DK2688474T3 (en) |
| WO (1) | WO2012130773A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6683230B2 (en) * | 2018-09-27 | 2020-04-15 | 横河電機株式会社 | measuring device |
| EP3646788A1 (en) * | 2018-10-31 | 2020-05-06 | Koninklijke Philips N.V. | Switch circuitry for a fluid monitoring device |
| USD1114649S1 (en) * | 2024-02-27 | 2026-02-24 | Roche Diabetes Care Gmbh | Analyte sensor assembly |
| USD1115575S1 (en) * | 2024-02-27 | 2026-03-03 | Roche Diabetes Care Gmbh | Analyte sensor assembly |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3035352B2 (en) | 1993-08-24 | 2000-04-24 | メトリカ・インコーポレーテッド | New disposable electronic test device |
| US6706159B2 (en) * | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
| US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
| DE10253154A1 (en) | 2002-11-14 | 2004-05-27 | Siemens Ag | Biosensor, used to identify analyte in liquid sample, has test field with detector, where detector registers field changes as electrical signals for evaluation |
| KR101165102B1 (en) * | 2003-09-03 | 2012-07-12 | 라이프 패치 인터내셔널, 인크. | Personal diagnostic devices and related methods |
| US7887682B2 (en) * | 2006-03-29 | 2011-02-15 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
-
2012
- 2012-03-23 US US14/007,178 patent/US8974747B2/en not_active Expired - Fee Related
- 2012-03-23 WO PCT/EP2012/055256 patent/WO2012130773A2/en not_active Ceased
- 2012-03-23 JP JP2014500418A patent/JP2014508950A/en not_active Abandoned
- 2012-03-23 DK DK12711155.7T patent/DK2688474T3/en active
- 2012-03-23 EP EP12711155.7A patent/EP2688474B1/en not_active Not-in-force
- 2012-03-23 CA CA2829499A patent/CA2829499A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2012130773A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014508950A (en) | 2014-04-10 |
| US8974747B2 (en) | 2015-03-10 |
| EP2688474B1 (en) | 2015-02-11 |
| CA2829499A1 (en) | 2012-10-04 |
| WO2012130773A3 (en) | 2012-11-22 |
| DK2688474T3 (en) | 2015-05-11 |
| WO2012130773A2 (en) | 2012-10-04 |
| US20140018652A1 (en) | 2014-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1799098B1 (en) | Multiple-biosensor article | |
| JP5785247B2 (en) | Electrochemical analyte measurement method and system | |
| US20100049021A1 (en) | Devices, systems, methods and tools for continuous analyte monitoring | |
| CA2743572A1 (en) | Devices, systems, methods and tools for continuous analyte monitoring | |
| TW202000135A (en) | Flexible ultra low profile transcutaneous continuous monitoring sensor | |
| JP2010525373A (en) | Test strip identification using conductive patterns | |
| EP2873969B1 (en) | Hematocrit measurement system and measurement method using the same | |
| EP2485043A1 (en) | Analyzing device, sensor testing device, testing method and testing program | |
| CA2931166C (en) | Dual-chamber analytical test strip | |
| EP1265530A1 (en) | Combined lancet and electrochemical analyte-testing apparatus | |
| EP2688474B1 (en) | Bodily fluid analysis device and method | |
| WO2012164271A1 (en) | Peak offset correction for analyte test strip | |
| WO2020099220A1 (en) | Device, system and method for estimating an analyte concentration in sweat as released by a sweat gland | |
| CN207202871U (en) | A kind of physiologic parameter analysis system continuously or discontinuously | |
| US7776608B2 (en) | Volume meter testing device and method of use | |
| US20130253294A1 (en) | Bodily fluid analysis device | |
| KR100832242B1 (en) | Glucose extraction patch and bloodless blood glucose measurement apparatus including the same | |
| KR200433455Y1 (en) | Glucose extraction patch and bloodless blood glucose measurement apparatus including the same | |
| Glennon | Development and application of a wearable device for real time potentiometric determination of electrolytes in sweat | |
| HK1227943B (en) | Dual-chamber analytical test strip | |
| HK1227943A1 (en) | Dual-chamber analytical test strip | |
| HK1179345A (en) | Electrochemical analyte measurement method and system | |
| HK1179345B (en) | Electrochemical analyte measurement method and system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20131025 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20140814 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 4 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 709654 Country of ref document: AT Kind code of ref document: T Effective date: 20150315 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012005233 Country of ref document: DE Effective date: 20150326 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20150310 Year of fee payment: 4 Ref country code: CH Payment date: 20150313 Year of fee payment: 4 Ref country code: DE Payment date: 20150317 Year of fee payment: 4 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20150508 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20150309 Year of fee payment: 4 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 709654 Country of ref document: AT Kind code of ref document: T Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150511 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20150619 Year of fee payment: 4 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150512 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150611 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012005233 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| 26N | No opposition filed |
Effective date: 20151112 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150323 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012005233 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20160331 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160323 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20161130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160323 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161001 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160331 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120323 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150611 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150323 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160323 |